LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Zurück zur letzten Suche Suchhistorie
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Tao Ming Sim"
  2. AU="Simen, Susanne"
  3. AU="Jole Costanza"
  4. AU="Paula, Camila S Y"
  5. AU="Azevedo, Helena S"
  6. AU=Molyneaux Phillip L.
  7. AU=Shimizu Kazuki
  8. AU=Pell Robert AU=Pell Robert
  9. AU="Aguiar, Liza"
  10. AU="Bahls, Christine"
  11. AU="Dongho Lee"
  12. AU=Houser Steven R.
  13. AU="Morgom M.M."
  14. AU="Jordana-Comajuncosa, Rosa"
  15. AU="Kaushansky, Alexis"
  16. AU="Bhatjiwale, Mohinish"
  17. AU="Velu, Chinavenmeni S"
  18. AU=Trayanova Natalia A
  19. AU=Jimeno-Gonzlez Silvia
  20. AU=Bussolino F
  21. AU="Almulla, Hanan"
  22. AU="Chen, Wenmei"
  23. AU=Zeng Weiqing

Suchergebnis

Treffer 1 - 3 von insgesamt 3

Suchoptionen

  1. Artikel ; Online: Nanoparticle-assisted targeting of the tumour microenvironment

    Tao Ming Sim

    OpenNano, Vol 8, Iss , Pp 100097- (2022)

    2022  

    Abstract: Cancer collectively represents a major, debilitating source of global disease burden. While we are just beginning to unravel the mysteries behind the multifarious pathways and mechanisms underpinning the complex process of tumourigenesis, advances in ... ...

    Abstract Cancer collectively represents a major, debilitating source of global disease burden. While we are just beginning to unravel the mysteries behind the multifarious pathways and mechanisms underpinning the complex process of tumourigenesis, advances in tumour biology have led to our current appreciation of the tumour microenvironment (TME). The TME is a dynamic, bidirectional crosstalk between malignant cells and the surrounding microenvironment comprising acellular components such as the extracellular matrix and cellular components which include immune cells and endothelium. Mounting evidence suggests that the TME is instrumental in reprogramming crucial oncogenic processes such as tumour initiation, growth, cellular energetics, invasion and metastasis. Given the significance of the TME, cancer research revolving around a targeted, TME-centric approach to treatment has been gaining traction. Nanoparticle (NP) technology offers a platform for the design of tissue-specific carrier system owing to its versatile and modifiable properties. The prospect of NPs targeting specific cellular or acellular components of the TME offers technical advantages such as high precision of tissue-specific drug delivery and therefore minimizing deleterious systemic toxicity and side effects. This review spotlights the updated image of the TME and its role in tumourigenesis, with emphasis on the hypoxic niche, immune microenvironment, acidic niche and extracellular matrix, before a discussion of NP-based treatment strategies to target the various pillars of the TME.
    Schlagwörter Nanoparticles ; Cancer ; Malignancy ; Tumour microenvironment ; TME ; Targeted medicine ; Therapeutics. Pharmacology ; RM1-950
    Thema/Rubrik (Code) 616
    Sprache Englisch
    Erscheinungsdatum 2022-11-01T00:00:00Z
    Verlag Elsevier
    Dokumenttyp Artikel ; Online
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Volltext online

    Zusatzmaterialien

    Kategorien

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  2. Artikel ; Online: Type I Interferons in Systemic Lupus Erythematosus

    Tao Ming Sim / Siying Jane Ong / Anselm Mak / Sen Hee Tay

    International Journal of Molecular Sciences, Vol 23, Iss 2505, p

    A Journey from Bench to Bedside

    2022  Band 2505

    Abstract: Dysregulation of type I interferons (IFNs) has been implicated in the pathogenesis of systemic lupus erythematosus (SLE) since the late 1970s. The majority of SLE patients demonstrate evidence of type I IFN pathway activation; however, studies attempting ...

    Abstract Dysregulation of type I interferons (IFNs) has been implicated in the pathogenesis of systemic lupus erythematosus (SLE) since the late 1970s. The majority of SLE patients demonstrate evidence of type I IFN pathway activation; however, studies attempting to address the relationship between type I IFN signature and SLE disease activity have yielded conflicting results. In addition to type I IFNs, type II and III IFNs may overlap and also contribute to the IFN signature. Different genetic backgrounds lead to overproduction of type I IFNs in SLE and contribute to the breakdown of peripheral tolerance by activation of antigen-presenting myeloid dendritic cells, thus triggering the expansion and differentiation of autoreactive lymphocytes. The consequence of the continuous stimulation of the immune system is manifested in different organ systems typical of SLE (e.g., mucocutaneous and cardiovascular involvement). After the discovery of the type I IFN signature, a number of different strategies have been developed to downregulate the IFN system in SLE patients, finally leading to the successful trial of anifrolumab, the second biologic to be approved for the treatment of SLE in 10 years. In this review, we will discuss the bench to bedside translation of the type I IFN pathway and put forward some issues that remain unresolved when selecting SLE patients for treatment with biologics targeting type I IFNs.
    Schlagwörter systemic lupus erythematosus ; SLE ; interferon ; IFN ; biologics ; anifrolumab ; Biology (General) ; QH301-705.5 ; Chemistry ; QD1-999
    Thema/Rubrik (Code) 610
    Sprache Englisch
    Erscheinungsdatum 2022-02-01T00:00:00Z
    Verlag MDPI AG
    Dokumenttyp Artikel ; Online
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Volltext online

    Zusatzmaterialien

    Kategorien

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  3. Artikel ; Online: Nanoparticle-Based Technology Approaches to the Management of Neurological Disorders

    Tao Ming Sim / Dinesh Tarini / S. Thameem Dheen / Boon Huat Bay / Dinesh Kumar Srinivasan

    International Journal of Molecular Sciences, Vol 21, Iss 6070, p

    2020  Band 6070

    Abstract: Neurological disorders are the most devastating and challenging diseases associated with the central nervous system (CNS). The blood-brain barrier (BBB) maintains homeostasis of the brain and contributes towards the maintenance of a very delicate ... ...

    Abstract Neurological disorders are the most devastating and challenging diseases associated with the central nervous system (CNS). The blood-brain barrier (BBB) maintains homeostasis of the brain and contributes towards the maintenance of a very delicate microenvironment, impairing the transport of many therapeutics into the CNS and making the management of common neurological disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), cerebrovascular diseases (CVDs) and traumatic brain injury (TBI), exceptionally complicated. Nanoparticle (NP) technology offers a platform for the design of tissue-specific drug carrying systems owing to its versatile and modifiable nature. The prospect of being able to design NPs capable of successfully crossing the BBB, and maintaining a high drug bioavailability in neural parenchyma, has spurred much interest in the field of nanomedicine. NPs, which also come in an array of forms including polymeric NPs, solid lipid nanoparticles (SLNs), quantum dots and liposomes, have the flexibility of being conjugated with various macromolecules, such as surfactants to confer the physical or chemical property desired. These nanodelivery strategies represent potential novel and minimally invasive approaches to the treatment and diagnosis of these neurological disorders. Most of the strategies revolve around the ability of the NPs to cross the BBB via various influx mechanisms, such as adsorptive-mediated transcytosis (AMT) and receptor-mediated transcytosis (RMT), targeting specific biomarkers or lesions unique to that pathological condition, thereby ensuring high tissue-specific targeting and minimizing off-target side effects. In this article, insights into common neurological disorders and challenges of delivering CNS drugs due to the presence of BBB is provided, before an in-depth review of nanoparticle-based theranostic strategies.
    Schlagwörter neurological disorders ; blood-brain barrier ; Alzheimer’s disease ; Parkinson’s disease ; cerebrovascular diseases ; traumatic brain injury ; Biology (General) ; QH301-705.5 ; Chemistry ; QD1-999
    Thema/Rubrik (Code) 610
    Sprache Englisch
    Erscheinungsdatum 2020-08-01T00:00:00Z
    Verlag MDPI AG
    Dokumenttyp Artikel ; Online
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Volltext online

    Zusatzmaterialien

    Kategorien

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

Zum Seitenanfang